Pseudomonas aeruginosa is a major player in United States nosocomial infections. This number approximates 51,000 cases each year. Individuals at risk of infection by P. aeruginosa are those that are exposed to hospital equipment that has not undergone proper sterilization (i.e., catheters, mechanical ventilation, etc.) Furthermore, certain P. aeruginosa strains mutate or endogenously produce β-Lactamase that provides resistance to penicillins. β-Lactamase disrupts the center atomic structure of several antibiotics including Penicillins, Cephalosporins, Monobactams, Carbapenems. Other mechanisms that provide intrinsic and obtained resistance to Penicillins include the genetically encoded efflux pumps; studied and assumed, act as transmembrane proteins assisting in the secretion of toxic material. Mutations influencing gene expression of P. aeruginosa may provide enough support to provide immunity to antimicrobials. These include depression of specific genes resulting in the production of extended spectrum β-Lactamase. The increase in immunity to penicillin and other antibiotics is an important factor in the length of a patient's hospital stay and mortality rate. Bacterial conjugation leads to an increase in antibiotic resistance even to the point that some specific strains of P. aeruginosa are immune to all penicillins. The illumination of P. aeruginosa has led to the implementation of many preventative measures and pre planned steps to fight nosocomial outbreaks. These measures of control have been stated to work well by some and their efficacy tested by others. This review attempts to address these resistance mechanisms and discuss the effectiveness of the preventative measures used today.
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : June 23, 2019